Program
CHS-1420
A development code.
Its studies are mostly in Psoriasis, led by 2 companies.
Furthest: phase 3, since Jul 1, 20152 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Coherus Biosciences | 10 open or running | phase 3since Jul 1, 2015 | Jul 1, 2015 | none ahead |
| Nanjing King-Friend Biochemical Pharmaceutical | 10 open or running | phase 1since Aug 12, 2025 | Aug 12, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 1, 2015First study: phase 3 study in Plaque PsoriasisNew to Coherus BiosciencesCoherus Biosciences · NCT02489227 · 545 enrolled · United States, Bulgaria, Canada and more
- Aug 12, 2025Nanjing King-Friend Biochemical Pharmaceutical's first study: phase 1 study in Healthy ParticipantsNew to Nanjing King-Friend Biochemical PharmaceuticalNanjing King-Friend Biochemical Pharmaceutical · NCT07147257 · 238 enrolled · China
TargetBeta
TNF →read by rule
“TNF-alpha inhibitor”ChEMBL 37, by rule
Other programs on TNF
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Adalimumabrule | Abbott | phase 4 | 153 |
| Brentuximab Vedotinrule | Pfizer | phase 4 | 37 |
| brivekimig | Sanofi | phase 2 | 6 |
| Hadlimarule | biora-therapeutics-inc | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07147257Healthy Participants · China | 1 | Completed | Nanjing King-Friend Biochemical Pharmaceutical | May 6, 2025 | 238 |
| NCT02489227Plaque Psoriasis · United States, Bulgaria, Canada and more | 3 | Completed | Coherus Biosciences | May 6, 2016 | 545 |
How it is read
Names in the registry
- “CHS-1420”, 2 entries
Codes read as this program: CHS1420.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.